Abstract
The present review aims at giving a condensed view on the current status of therapy of atopic eczema - a common chronically relapsing inflammatory skin disease. Atopic eczema is a multifactorial disease with a tendency for chronification. Owing to the associated genetic factors, therapeutic amelioration of skin symptoms is often only transient. Therefore, treatment basically focuses on symptomatic relief. Atopic eczema treatment should more than any other disease be guided by an individualized approach taking not only the phenotype and genotype of the disease but also psychosocial and gender aspects into account. Significant gains have been made in our understanding of atopic eczema, especially recent insights into genetic and immunologic mechanisms, but still, there is no single treatment to date that has proven to be the quantum leap for atopic patients. Novel treatments have been developed and trialled, however, more studies on novel therapies such as biologicals addressing efficacy, optimum dose and duration of treatment and the target phenotype are urgently needed. Hopefully, the tremendous progress in basic research in the last years will provide new targets for prevention and treatment in the future.
Keywords: Atopic eczema, pernonalized therapy
Current Drug Metabolism
Title: Therapeutic Management of Atopic Eczema
Volume: 11 Issue: 3
Author(s): Claudia Traidl-Hoffmann, Martin Mempel, Benedetta Belloni, Johannes Ring and Christina Schnopp
Affiliation:
Keywords: Atopic eczema, pernonalized therapy
Abstract: The present review aims at giving a condensed view on the current status of therapy of atopic eczema - a common chronically relapsing inflammatory skin disease. Atopic eczema is a multifactorial disease with a tendency for chronification. Owing to the associated genetic factors, therapeutic amelioration of skin symptoms is often only transient. Therefore, treatment basically focuses on symptomatic relief. Atopic eczema treatment should more than any other disease be guided by an individualized approach taking not only the phenotype and genotype of the disease but also psychosocial and gender aspects into account. Significant gains have been made in our understanding of atopic eczema, especially recent insights into genetic and immunologic mechanisms, but still, there is no single treatment to date that has proven to be the quantum leap for atopic patients. Novel treatments have been developed and trialled, however, more studies on novel therapies such as biologicals addressing efficacy, optimum dose and duration of treatment and the target phenotype are urgently needed. Hopefully, the tremendous progress in basic research in the last years will provide new targets for prevention and treatment in the future.
Export Options
About this article
Cite this article as:
Traidl-Hoffmann Claudia, Mempel Martin, Belloni Benedetta, Ring Johannes and Schnopp Christina, Therapeutic Management of Atopic Eczema, Current Drug Metabolism 2010; 11 (3) . https://dx.doi.org/10.2174/138920010791196319
DOI https://dx.doi.org/10.2174/138920010791196319 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides
Current Protein & Peptide Science P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism DNA Polymerases and Oxidative Damage: Friends or Foes?
Current Molecular Pharmacology Herpesvirus Saimiri-Based Gene Delivery Vectors
Current Gene Therapy Diterpenoids- Potential Chemopreventive and Chemotherapeutic Agents in Leukemia
Current Pharmaceutical Biotechnology Indole-based, Antiproliferative Agents Targeting Tubulin Polymerization
Current Topics in Medicinal Chemistry Intracellular Logistics of BST-2/Tetherin
Current HIV Research Ultraviolet B Regulation of Transcription Factor Families: Roles of Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1) in UVB-Induced Skin Carcinogenesis
Current Cancer Drug Targets Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Recent Advances in Coumarins and 1-Azacoumarins as Versatile Biodynamic Agents
Current Medicinal Chemistry Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Current Pharmaceutical Design Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015
Current Medicinal Chemistry Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine